iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$9.55 USD
+0.13 (1.38%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $9.54 -0.01 (-0.10%) 5:28 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.55 USD
+0.13 (1.38%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $9.54 -0.01 (-0.10%) 5:28 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics (ITOS) delivered earnings and revenue surprises of 82.69% and 733.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 243.4% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 283.6% in iTeos Therapeutics, Inc. (ITOS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for iTeos Therapeutics, Inc. (ITOS) points to a 304.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak
by Zacks Equity Research
Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study
by Zacks Equity Research
Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.
ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 55.56% and 8.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 138.89% and 89.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -58.33% and 21.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
ITeos Therapeutics, Inc. (ITOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -87.50% and 56.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is BioNTech (BNTX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 127.50% and 140.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
by Zacks Equity Research
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
Why iTeos Therapeutics, Inc. (ITOS) Might be Well Poised for a Surge
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 53%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 53.3% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.